XTANDI (enzalutamide) 40 mg capsules are supplied as white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ and are available in the following package size:
- Bottles of 120 capsules with child resistant closures (NDC 0469-0125-99)
XTANDI (enzalutamide) 40 mg tablets are supplied as yellow, round, film-coated tablets debossed with E 40, and are available in the following package size:
- Bottles of 120 tablets with child resistant closures (NDC 0469-0625-99)
XTANDI (enzalutamide) 80 mg tablets are supplied as yellow, oval, film-coated tablets debossed with E 80, and are available in the following package size:
- Bottles of 60 tablets with child resistant closures (NDC 0469-0725-60)
Recommended storage: Store XTANDI capsules and tablets at 20°C to 25°C (68°F to 77°F) in a dry place and keep the container tightly closed. Excursions permitted from 15°C to 30°C (59°F to 86°F).
Swallow capsules or tablets whole. Do not chew, dissolve or open the capsules. Do not cut, crush, or chew the tablets.
Advise the patient to read the FDA-approved patient labeling (Patient Information).
- Inform patients that XTANDI has been associated with an increased risk of seizure. Discuss conditions that may predispose to seizures and medications that may lower the seizure threshold. Advise patients of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Inform patients to contact their healthcare provider right away if they have loss of consciousness or seizure [see Warnings and Precautions (5.1)].
Posterior Reversible Encephalopathy Syndrome (PRES)
- Inform patients to contact their healthcare provider right away if they experience rapidly worsening symptoms possibly indicative of PRES such as seizure, headache, decreased alertness, confusion, reduced eyesight, or blurred vision [see Warnings and Precautions (5.2)].
- Inform patients that XTANDI may be associated with hypersensitivity reactions that include swelling of the face, lip, tongue, or throat [see Warnings and Precautions (5.3)]. Advise patients who experience these types of symptoms of hypersensitivity to discontinue XTANDI and promptly contact their healthcare provider.
Ischemic Heart Disease
- Inform patients that XTANDI has been associated with an increased risk of ischemic heart disease. Advise patients to seek immediate medical attention if any symptoms suggestive of a cardiovascular event occur [see Warnings and Precautions (5.4)].
Falls and Fractures
- Inform patients that XTANDI is associated with an increased incidence of dizziness/vertigo, falls, and fractures. Advise patients to report these adverse reactions to their healthcare provider [see Warnings and Precautions ( 5.5)].
- Inform patients that XTANDI is associated with an increased incidence of hypertension [see Adverse Reactions (6.1)].
Dosing and Administration
- Inform patients who have not undergone bilateral orchiectomy and are receiving GnRH therapy that they need to maintain this treatment during the course of treatment with XTANDI.
- Instruct patients to take their dose at the same time each day (once daily). XTANDI can be taken with or without food. Each capsule or tablet should be swallowed whole. Do not chew, dissolve, or open the capsules. Do not cut, crush, or chew the tablets.
- Inform patients that they should not interrupt, modify the dose, or stop XTANDI without first consulting their healthcare provider.
- Inform patients that if they miss a dose, then they should take it as soon as they remember. If they forget to take the dose for the whole day, then they should take their normal dose the next day. They should not take more than their prescribed dose per day [see Dosage and Administration (2.1)].
- Inform patients that XTANDI can be harmful to a developing fetus and can cause loss of pregnancy.
- Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of XTANDI. Advise male patients to use a condom if having sex with a pregnant woman [see Warnings and Precautions (5.6)].
- Inform male patients that XTANDI may impair fertility [see Use in Specific Populations (8.3)].
Manufactured for and Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062
Astellas Pharma US, Inc., Northbrook, IL 60062 Pfizer Inc., New York, NY 10017
Rx Only © 2020 Astellas Pharma US, Inc.
XTANDI® is a registered trademark of Astellas Pharma Inc.
XTANDI® (ex TAN dee)
Capsules and Tablets
What is XTANDI® ?
XTANDI is a prescription medicine used to treat men with prostate cancer that:
It is not known if XTANDI is safe and effective in females.
It is not known if XTANDI is safe and effective in children.
Before taking XTANDI, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works.
You should not start or stop any medicine before you talk with the healthcare provider that prescribed XTANDI.
Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine.
How should I take XTANDI?
If you take too much XTANDI, call your healthcare provider or go to the nearest emergency room right away. You may have an increased risk of seizure if you take too much XTANDI.
What are the possible side effects of XTANDI?
XTANDI may cause serious side effects including:
Your healthcare provider will stop treatment with XTANDI if you have serious side effects.
The most common side effects of XTANDI include:
| || |
XTANDI may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of XTANDI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store XTANDI?
Keep XTANDI and all medicines out of the reach of children.
General information about the safe and effective use of XTANDI.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use XTANDI for a condition for which it was not prescribed. Do not give XTANDI to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your healthcare provider or pharmacist for information about XTANDI that is written for health professionals.
What are the ingredients in XTANDI?
Active ingredient: enzalutamide
Inactive ingredients: caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, black iron oxide
Active ingredient: enzalutamide
Inactive ingredients: hypromellose acetate succinate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, and magnesium stearate.
The tablet film-coat contains hypromellose, talc, polyethylene glycol, titanium dioxide, and ferric oxide.Manufactured for and Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062
Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062 Pfizer Inc., New York, NY 10017
© 2020 Astellas Pharma US, Inc.
XTANDI® is a registered trademark of Astellas Pharma Inc. For more information go to www.Xtandi.com or call 1-800-727-7003.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: August 2020
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.